Introduction
Epidemiologic studies published in 1995 reported a slightly higher risk of venous thromboembolism among users of oral contraceptives (OCs) containing desogestrel or gestodene as the progestogenic component (third generation OCs) as than among users of OCs containing levonorgestrel or norgestimate as the progestogenic component (second-generation OCs (1, 2) . Oral oestrogen use in women has been associated with increased risk of venous thromboembolism. In premenopausal women, the risk of venous thromboembolism has been shown to increase by about two to six-fold during the use of combined oral contraceptives, (3) . Due to the observed differences in the risk of VT induced by OC containing the same dose of estrogen but different progestogen compounds, the prothrombotic effect of the pill was considered to be not strictly dependent on the dose of estrogen but rather on the "total estrogenicity" of the formulation (4). The "total estrogenicity" rises with increasing dose of estrogen but decreases with increasing antiestrogenic activity of progestogen compound. It was suggested that third generation progestogens, as well as drospirenone and cyproterone acetate possess a weaker anti-estrogenic activity than levonorgestrel and, therefore, are less potent in the counterbalancing the prothrombotic effects of estrogen (4, 5) . Consequently, OC containing third generation progestogens (desogestrel or gestodene), drospirenone or cyproterone acetate have a higher "total estrogenicity" as compared to second generation OC which may explain why users of these formulations are exposed to a higher thrombotic risk (5) . Heritable thrombophilia is another thrombotic factor that include deficiencies of antithrombin, protein C and protein S; and common genetic mutations such as factor V Leiden and the prothrombin G20210A mutation (6) . Other relatively common thrombophilias with a combination of heritable and acquired components include elevated plasma factor VIIIc (7), hyperhomocysteinaemia (8) and acquired activated protein C resistance (9) . The further increased thrombotic risk in third generation OC users was, however, questioned in later publications (10, 11, 12) . The discussion that followed was hampered by the fact that there was neither a good biological explanation for the thrombotic effect of the pill nor for the difference between second and third generation oral contraceptives (13) . Therefore the aim of this study was to determine the effect of two combined oral contraceptives (containing: ethinylestradiol/levonogestrel and ethinylestradiol/ gestodene) on protein C and antithrombin III concentrations in a group of healthy Albanian women.
Material and methods
Study design: The study was carried out at Ana Diagnostic Center, in Tirana, Albania. Healthy women requesting contraception were included and followed up for two months. Twenty six women were instructed to use COC with 30 µg EE and 75 µg GSD and thirty were instructed to use COC with 30 µg EE and 75 µg LNG, initiating pill intake on the first day of the cycle. Clinical and laboratory assessments were carried out prior to initiation of medication (pretreatment) and after 2 months of COC use. Laboratory methods: All participants were submitted to a blood collection to perform the antithrombin III and protein C laboratory test. Blood samples were centrifuged at 1500 rev/min for 15 min to extract plasma. We used chromogenic assay (Cobas 6000, Roche) to evaluate antithrombin III while protein C was evaluated via ELFA (Vidas, Biomerieux). Statistical analyses: Student's t-test for paired samples was used for numerical variables to compare levels of inhibitory coagulation proteins at two time intervals (pre-treatment and after 2 months of COCs use). Statistical significance (p<0.05) was determined using SPSS 20 software.
Results
Comparison of the values of protein C and AT III between two periods (before and after treatment) showed the following results: concentrations of protein C was significantly increased (p=0.001) while AT III level was reduced after treatment with 30μg EE/75μg GSD (p=0.001). Treatment with 30μg EE/75μg LNG showed no significant change in the level of AT III (p=0.058) and significantly increased protein C concentration (p=0.001), ( 
Discussions
This study showed that use of combined oral contraceptives leads to significant changes in protein C and antithrombin III plasma concentrations. The investigation found a large effect of oestrogen and progestogen on protein C. A greater change but not significant in protein C level was observed in the GSD group compared with the LNG group. Comparison between treatments reported the same effect on protein C concentration (p=0.36; table 2). Our results of a rise in protein C activity during use of both formulations confirm those of previous OC studies (12, 14, 15) . (17) . OC use causes considerable alterations in the anticoagulant system (Table 1) , decreasing the plasma level of the major inhibitor of several activated coagulation factors, antithrombin III (17) . Pronounced changes occur also in the protein C pathway. OC induce a small increase in the concentration and activity of protein C, which is reported to be counterbalanced by elevated levels of the major protein C inhibitors, i.e. protein C inhibitor, α1-antitrypsin (α1-antiprotease) and α2-macroglobulin (5). Based on our results we conclude that the use of a COCs containing 30 µg EE/75 µg GSD for a period of two months in healthy women with no associated risk factors caused significant changes in protein C and AT III levels. Treatment with 30 µg EE/75 µg LNG showed no significant change in AT III plasma concentration and significantly increased protein C level. The clinical significance of these findings should be evaluated in a larger cohort study.
